Thomas O. Hecht

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Humabs BioMed SA is an antibody therapeutics biotechnology company. It develops human monoclonal antibody platforms for treatment of infectious and inflammatory diseases. The company was founded by Prof. Antonio Lanzavecchia on October 24, 2011 and is headquartered in Bellinzona, Switzerland.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany.

The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year.

A department of the province of Québec, the Société Générale de Financement du Québec (SGF) provides development capital for businesses. They are headquartered in Montreal with offices in Québec and Saint-Hyacinthe. The firm was founded in 1962.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Orion Biotechnology Canada Ltd. operates as pharmaceutical company. The company was founded by Rudolf Bom in 2011 and is headquartered in Ottawa, Canada.